



Supplementary Materials:




Supplementary Figure S1: Evaluation of cell viability post treatment with different sets of combination of free gefitinib and free GSK461364A

(2A)




(2B)




Supplementary Figure S2 : Peak absorbance of **(2A)** gefitinib at 331nm dissolved in 1% Triton-x, with GSK461364A as blank **(2B)** GSK461364A at 311nm with gefitinib as blank

(3A)


	Size (d.nm):	% Intensity:	St Dev (d.nm):
Z-Average (d.nm): 122.1	Peak 1: 135.5	100.0	43.99
Pdl: 0.091	Peak 2: 0.000	0.0	0.000
Intercept: 0.966	Peak 3: 0.000	0.0	0.000
Result quality : Good			




(3B)



(3C)



Supplementary Figure S3: (A) Size distribution by intensity with the average size being ~122 nm. (B) Phase plot of zeta potential plotted against time (C) Zeta potential distribution with total counts plotted against apparent zeta potential. Average zeta potential was ~20 mV.



Supplementary Figure S4: Effective concentration (EC₅₀) curve of gefitinib in U87-MG cell line plotted using Dr.Fit® software. These data points follow monophasic model (standard Hill equation).